Sino Biopharmaceutical Limited (OTCMKTS:SBMFF) Sees Large Decline in Short Interest

Sino Biopharmaceutical Limited (OTCMKTS:SBMFF - Get Free Report) was the target of a large drop in short interest in March. As of March 31st, there was short interest totalling 15,300,300 shares, a drop of 79.5% from the March 15th total of 74,612,700 shares. Currently, 0.1% of the company's stock are sold short. Based on an average daily volume of 1,500 shares, the days-to-cover ratio is currently 10,200.2 days.

Sino Biopharmaceutical Price Performance

OTCMKTS:SBMFF remained flat at $0.47 during trading hours on Friday. Sino Biopharmaceutical has a twelve month low of $0.31 and a twelve month high of $0.47. The stock's 50 day moving average is $0.43 and its two-hundred day moving average is $0.43. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.15 and a quick ratio of 1.07.

Sino Biopharmaceutical Company Profile

Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, pomalidomide capsules under Anyue brand, bevacizumab injection under Anbeisi brand, rituximab injection under Delituo brand, and trastuzumab for injection under Saituo brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand and colistimethate sodium for injection under Tianyun brand.